Table 2 Clinical and physiological comparisons between subgroups defined based on symptoms and physical activity questionnaires.
Less symptomatic (CAT < 10) | Symptomatic (CAT ≥ 10) | |||
---|---|---|---|---|
LSA > 60 (n = 82) | LSA ≤ 60 (n = 11) | LSA > 60 (n = 73) | LSA ≤ 60 (n = 27) | |
Age | 72.1 ± 6.4 | 74.0 ± 6.9 | 71.9 ± 8.4 | 74.3 ± 9.6 |
Male, n (%) | 79 (96%) | 9 (82%) | 67 (92%) | 25 (93%) |
Pack-years | 60.0 ± 30.7 | 76.1 ± 39.2 | 57.8 ± 28.7 | 60.9 ± 33.7 |
Height, cm | 166.7 ± 6.5 | 160.2 ± 8.4 | 164.9 ± 6.9 | 163.3 ± 8.3 |
BMI, kg/m2 | 23.8 ± 3.2 | 23.3 ± 3.0 | 23.6 ± 3.6 | 20.0 ± 4.2*†‡ |
No. exacerbations in a previous year, 0/1/ ≥ 2 | 68/13/1 | 11/0/0 | 50/19/4 | 19/5/3 |
FEV1, % predicted | 69.1 ± 20.4 | 71.3 ± 16.1 | 60.4 ± 23.3 | 45.4 ± 19.3*†‡ |
FVC, % predicted | 95.0 ± 20.5 | 90.4 ± 6.4 | 87.9 ± 2.5 | 75.2 ± 4.1*‡ |
GERD | 7 (9%) | 2 (18%) | 21 (29%) * | 3 (11%) |
Allergic rhinitis | 10 (12.1%) | 0 (0%) | 12 (16.4%) | 1 (3.7%) |
Hypertension | 41 (50%) | 5 (45%) | 48 (66%) | 11 (41%) |
IHD | 13 (16%) | 1 (9%) | 12 (16%) | 1 (4%) |
DM | 9 (11%) | 2 (18%) | 12 (16%) | 2 (7%) |
LAMA use, n (%) | 43 (52%) | 7 (64%) | 46 (63%) | 23 (85%) * |
LABA use, n (%) | 46 (56%) | 5 (45%) | 52 (71%) | 20 (74%) |
ICS use, n (%) | 32 (39%) | 2 (18%) | 37 (51%) | 11 (41%) |